A major weapon against cancer

  • The cancer immunotherapy market for checkpoint inhibitors will increase to nearly $9 billion across the world’s major pharmaceutical markets in 2022.
  • The successes of immunotherapies dominate the literature and drive current research on cancer.
  • Immune approaches to cancer therapy have been validated by the approval of drugs such as Keytruda®, Opdivo®, Yervoy® and Provenge®.
  • Immune modulators such as anti-PD-1 (Keytruda®)/anti-PD-L1 (Tecentriq®) mAb’s boost T-cell activity in response to tumors and are widely used  in high priority therapeutic development programs by Big Pharma.
  • Side effects are significant but manageable.
  • Analysts estimate that cancer immunotherapies could account for $35 billion annually within 10 years

The Susavion advantage

  • Susavion’s multivalent peptide technology engages strategic targets on multiple cell types that stimulate proliferation and maturation of active lymphocytic and monocytic immune cells, thereby expanding the innate immune system.
  • Susavion’s lead drug promotes maturation of dendritic cells and presentation of antigens to T cells to initiate a humoral immune response.
  • Susavion developed several peptides that turn on activating receptors and other peptides that turn off inhibitory receptors (checkpoint blockade) on key immune cells.
  • Susavion’s peptides are excellent complements and extend the efficacy of other immunotherapies.
  • Susavion’s platform drugs are produced synthetically, relatively inexpensive to produce at high purity, stable, and easily distributed world-wide.
  • Susavion’s drugs have broad application against cancers, low toxicity, and thus are potentially game changers.